Media event on the latest data from the RE-LY® trial, recent sub-group analyses and the implications for guidelines and daily practice.

1 Mission 1 Million - Getting to the Heart of Stroke - is a global disease awareness initiative that aims to help prevent as many as 1 million atrial fibrillation-related strokes through increased awareness and understanding.

Success through inquiring minds and innovations.
Boehringer Ingelheim celebrates its 125-year existence and looks to the future with confidence.

New phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile.

Boehringer Ingelheim is developing new treatments that target and inhibit the key biological pathways involved in stimulating angiogenesis, thereby preventing growth and spread of the tumour.

Boehringer Ingelheim presents results of the business year 2009 and outlook 2010 at the Annual Press Conference, 20 April 2010.

The RE-COVER trial results shed light on an important indication for anticoagulation: Acute Venous Thromboembolism.